Literature DB >> 34604321

Netherton Syndrome: Case Report and Review of the Literature.

Maira E Herz-Ruelas1, Sonia Chavez-Alvarez1, Juana Irma Garza-Chapa1, Jorge Ocampo-Candiani1, Victor Andres Cab-Morales2, David Emmanuel Kubelis-López1.   

Abstract

Netherton syndrome (NS) is a rare genodermatosis with an autosomal recessive pattern of inheritance caused by pathogenic variants in the SPINK5 gene. It is characterized by a triad consisting of atopic diathesis, ichthyosis linearis circumflexa, and hair shaft abnormalities. Ichthyosis linearis circumflexa can be confused with atopic dermatitis leading to a delayed diagnosis. Furthermore, difficulty in making the differential diagnosis with other atopiform, erythrodermic, and ichthyosiform entities that exhibit hair shaft abnormalities represent a challenge. Trichoscopy is an accessible and noninvasive auxiliary diagnostic tool in these cases; the hair shaft abnormalities found in NS are bamboo, golf tee, and matchstick hairs. Identification of a pathogenic variant in the SPINK5 gene through genetic testing is necessary to confirm the diagnosis. Multiple treatment options are available including topical therapy with emollients, corticosteroids, calcineurin inhibitors, antiseptics, and narrowband UVB phototherapy. Systemic treatments comprehend intravenous immunoglobulins, and advances in the understanding of the pathophysiology of NS have led to more directed therapies with biologics such as infliximab, ixekizumab, secukinumab, ustekinumab, and dupilumab. Treatments currently under investigation include inhibitors of kallikrein 5, cathelicidins, drugs activating the transcription factor nuclear factor erythroid-derived 2-like 2, and gene therapy using autologous keratinocytes induced with a lentiviral vector encoding SPINK5.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Ichthyosis linearis circumflexa; Netherton syndrome; Trichorrhexis invaginata

Year:  2021        PMID: 34604321      PMCID: PMC8436607          DOI: 10.1159/000514699

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  15 in total

Review 1.  Netherton syndrome: a case report and review of the literature.

Authors:  Joannie D Sun; Kenneth G Linden
Journal:  Int J Dermatol       Date:  2006-06       Impact factor: 2.736

2.  The challenging management of a series of 43 infants with Netherton syndrome: unexpected complications and novel mutations.

Authors:  N Bellon; S Hadj-Rabia; F Moulin; C Lambe; G Lezmi; F Charbit-Henrion; C Alby; L Le Saché-de Peufeilhoux; S Leclerc-Mercier; A Hadchouel; J Steffann; A Hovnanian; A Lapillonne; C Bodemer
Journal:  Br J Dermatol       Date:  2020-09-10       Impact factor: 9.302

3.  Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin.

Authors:  Lionel Fontao; Emmanuel Laffitte; Anais Briot; Gürkan Kaya; Pascale Roux-Lombard; Sylvie Fraitag; Alain A Hovnanian; Jean-Hilaire Saurat
Journal:  J Invest Dermatol       Date:  2011-06-09       Impact factor: 8.551

4.  Management of congenital ichthyoses: European guidelines of care, part two.

Authors:  J Mazereeuw-Hautier; A Hernández-Martín; E A O'Toole; A Bygum; C Amaro; M Aldwin; A Audouze; C Bodemer; E Bourrat; A Diociaiuti; M Dolenc-Voljč; I Dreyfus; M El Hachem; J Fischer; A Ganemo; C Gouveia; R Gruber; S Hadj-Rabia; D Hohl; N Jonca; K Ezzedine; D Maier; R Malhotra; M Rodriguez; H Ott; D G Paige; A Pietrzak; F Poot; M Schmuth; J C Sitek; P Steijlen; G Wehr; M Moreen; A Vahlquist; H Traupe; V Oji
Journal:  Br J Dermatol       Date:  2018-12-03       Impact factor: 9.302

5.  Management of congenital ichthyoses: European guidelines of care, part one.

Authors:  J Mazereeuw-Hautier; A Vahlquist; H Traupe; A Bygum; C Amaro; M Aldwin; A Audouze; C Bodemer; E Bourrat; A Diociaiuti; M Dolenc-Voljc; I Dreyfus; M El Hachem; J Fischer; A Gånemo; C Gouveia; R Gruber; S Hadj-Rabia; D Hohl; N Jonca; K Ezzedine; D Maier; R Malhotra; M Rodriguez; H Ott; D G Paige; A Pietrzak; F Poot; M Schmuth; J C Sitek; P Steijlen; G Wehr; M Moreen; E A O'Toole; V Oji; A Hernandez-Martin
Journal:  Br J Dermatol       Date:  2018-12-03       Impact factor: 9.302

6.  Netherton Syndrome Mimicking Pustular Psoriasis: Clinical Implications and Response to Intravenous Immunoglobulin.

Authors:  Alison M Small; Kelly M Cordoro
Journal:  Pediatr Dermatol       Date:  2016-04-18       Impact factor: 1.588

7.  Secukinumab Therapy for Netherton Syndrome.

Authors:  Isabelle Luchsinger; Nicole Knöpfel; Martin Theiler; Mathilde Bonnet des Claustres; Claire Barbieux; Agnes Schwieger-Briel; Corinne Brunner; Davide Donghi; Michael Buettcher; Barbara Meier-Schiesser; Alain Hovnanian; Lisa Weibel
Journal:  JAMA Dermatol       Date:  2020-08-01       Impact factor: 10.282

8.  Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl.

Authors:  S Volc; L Maier; A Gritsch; M C Aichelburg; B Volc-Platzer
Journal:  Br J Dermatol       Date:  2020-03-09       Impact factor: 9.302

9.  Response to dupilumab in two children with Netherton syndrome: Improvement of pruritus and scaling.

Authors:  K Süßmuth; H Traupe; K Loser; S Ständer; C Kessel; H Wittkowski; V Oji
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-09-25       Impact factor: 6.166

10.  Infliximab therapy for Netherton syndrome: A case report.

Authors:  Ângela Roda; Maria Mendonça-Sanches; Ana Rita Travassos; Luís Soares-de-Almeida; Dieter Metze
Journal:  JAAD Case Rep       Date:  2017-11-06
View more
  2 in total

1.  A novel mutation in SPINK5 gene underlies a case of atypical Netherton syndrome.

Authors:  Yu Wang; Hanqing Song; Lingling Yu; Nan Wu; Xiaodong Zheng; Bo Liang; Peiguang Wang
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

2.  Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome.

Authors:  Salem M Tos; Bilal Nabeel Alqam; Narmeen Giacaman; Mohammad G Ibdah; Mahmoud M M Gabajah; Abdallah Altell
Journal:  Ann Med Surg (Lond)       Date:  2022-08-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.